Loading...
Derniers manuscrits de l'équipe
-
Benjamin Villalard, Arjan Boltjes, Florie Reynaud, Olivier Imbaud, Karine Thoinet, et al.. Neuroblastoma plasticity during metastatic progression stems from the dynamics of an early sympathetic transcriptomic trajectory. Nature Communications, 2024, 15 (1), pp.9570. ⟨10.1038/s41467-024-53776-3⟩. ⟨hal-04772741⟩
-
Anne-Laure Désage, Michaël Duruisseaux, Claire Lafitte, Sophie Bayle-Bleuez, Christos Chouaid, et al.. Toxicities associated with sequential or combined use of immune checkpoint inhibitors and small targeted therapies in non-small cell lung cancer: A critical review of the literature. Cancer Treatment Reviews, 2024, 129, ⟨10.1016/j.ctrv.2024.102805⟩. ⟨hal-04728403⟩
-
Christophe Marquette, Laura Chastagnier, Benjamin da Sousa, Carlos Chocarro-Wrona, Edwin-Joffrey Courtial, et al.. Unlocking the potential of bio-inspired bioinks: A collective breakthrough in mammalian tissue bioprinting. Bioprinting , 2024, 41, pp.e00351. ⟨10.1016/j.bprint.2024.e00351⟩. ⟨hal-04729007⟩
-
Oliver Illini, Felix Carl Saalfeld, Petros Christopoulos, Michaël Duruisseaux, Anders Vikström, et al.. Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy Analysis. International Journal of Molecular Sciences, 2024, 25, ⟨10.3390/ijms25073992⟩. ⟨hal-04728435⟩
-
Hippolyte Darré, Perrine Masson, Arnaud Nativel, Laura Villain, Diane Lefaudeux, et al.. Comparing the Efficacy of Two Generations of EGFR-TKIs: An Integrated Drug–Disease Mechanistic Model Approach in EGFR-Mutated Lung Adenocarcinoma. Biomedicines, 2024, 12, ⟨10.3390/biomedicines12030704⟩. ⟨hal-04728446⟩
Chiffres clés
99
Publications avec texte intégral